Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ: ELOX ยท Real-Time Price ยท USD
10.65
+0.24 (2.31%)
At close: Nov 19, 2026, 4:00 PM EST
10.66
+0.01 (0.09%)
After-hours: Nov 19, 2026, 4:10 PM EST
Eloxx Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
ELX-02 targets nonsense mutations in Alport syndrome and ADPKD, with Alport phase II data expected mid-2027. An ADPKD study is planned to start enrollment in Q3 2027, with data expected H1 2029; cash runway is expected into mid-2028.